Used in the treatment of type 2 diabetes, dorzagliatin helps regulate blood glucose levels by targeting pancreatic beta cells and liver cells to restore glucose-sensing function. It works by modulating glucokinase, an enzyme involved in glucose metabolism, which enhances insulin secretion in response to elevated blood sugar and reduces excessive glucose production in the liver. This dual action supports better glycemic control without increasing the risk of hypoglycemia. It is taken orally and is particularly beneficial for patients who need improved glucose homeostasis early in the disease progression. Clinical studies show it can be effective as monotherapy or in combination with other antidiabetic agents like metformin.